Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2017

Open Access 01-12-2017 | Review

Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?

Authors: Shan-shan Yu, Jian-ling Du

Published in: Cardiovascular Diabetology | Issue 1/2017

Login to get access

Abstract

Inflammatory response, oxidative stress, and endoplasmic reticulum (ER) stress are important pathophysiological bases of the occurrence and development of diabetes mellitus (DM) and macroangiopathy complications. Selenoprotein S (SELENOS) is involved in the regulation of these mechanisms; therefore, its association with DM and macroangiopathy has gradually received attention from scholars worldwide. SELENOS has different biological functions in different tissues and organs: it exerts antioxidant protection and has anti-ER stress effects in the pancreas and blood vessels, while it promotes the occurrence and development of insulin resistance in the liver, adipose tissue, and skeletal muscle. In addition, studies have confirmed that some SELENOS gene polymorphisms can influence the inflammatory response and are closely associated with the risk for developing DM and macroangiopathy. Therefore, comprehensive understanding of the association between SELENOS and inflammation, oxidative stress, and ER stress may better elucidate and supplement the pathogenic mechanisms of DM and macroangiopathy complications. Furthermore, in-depth investigation of the association of SELENOS function in different tissues and organs with DM and macroangiopathy may facilitate the development of new strategies for the prevention and treatment of DM and macrovascular complications. Here, we summarize the consensus and controversy regarding functions of SELENOS on currently available evidence.
Literature
1.
(NCD-RisC). NRFC. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet (London, England). 2016;387(10027):1513–30.CrossRef
2.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–60.CrossRefPubMed
3.
4.
Su W, Zhang Y, Zhang Q, Xu J, Zhan L, Zhu Q, Lian Q, Liu H, Xia ZY, Xia Z. N-acetylcysteine attenuates myocardial dysfunction and postischemic injury by restoring caveolin-3/eNOS signaling in diabetic rats. Cardiovasc Diabetol. 2016;15(1):146.CrossRefPubMedPubMedCentral
5.
Wu D, Terrian DM. Regulation of caveolin-1 expression and secretion by a protein kinase cepsilon signaling pathway in human prostate cancer cells. J Biol Chem. 2002;277(43):40449–55.CrossRefPubMed
6.
Safarinejad MR, Safarinejad S. Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. J Urol. 2009;181(2):741–51.CrossRefPubMed
7.
Sarkozy M, Szucs G, Pipicz M, Zvara A, Eder K, Fekete V, Szucs C, Barkanyi J, Csonka C, Puskas LG, et al. The effect of a preparation of minerals, vitamins and trace elements on the cardiac gene expression pattern in male diabetic rats. Cardiovasc Diabetol. 2015;14:85.CrossRefPubMedPubMedCentral
8.
9.
Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN. Characterization of mammalian selenoproteomes. Science. 2003;300(5624):1439–43.CrossRefPubMed
10.
Arner ES. Selenoproteins-What unique properties can arise with selenocysteine in place of cysteine? Exp Cell Res. 2010;316(8):1296–303.CrossRefPubMed
11.
12.
Gladyshev VN, Arner ES, Berry MJ, Brigelius-Flohe R, Bruford EA, Burk RF, Carlson BA, Castellano S, Chavatte L, Conrad M, et al. Selenoprotein gene nomenclature. J Biol Chem. 2016;291(46):24036–40.CrossRefPubMed
13.
Steinbrenner H. Interference of selenium and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism. Free Radic Biol Med. 2013;65:1538–47.CrossRefPubMed
14.
Walder K, Kantham L, McMillan JS, Trevaskis J, Kerr L, De Silva A, Sunderland T, Godde N, Gao Y, Bishara N, et al. Tanis: a link between type 2 diabetes and inflammation? Diabetes. 2002;51(6):1859–66.CrossRefPubMed
15.
Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature. 2004;429(6994):841–7.CrossRefPubMed
16.
Gao Y, Hannan NR, Wanyonyi S, Konstantopolous N, Pagnon J, Feng HC, Jowett JB, Kim KH, Walder K, Collier GR. Activation of the selenoprotein SEPS1 gene expression by pro-inflammatory cytokines in HepG2 cells. Cytokine. 2006;33(5):246–51.CrossRefPubMed
17.
Fradejas N, Serrano-Perez Mdel C, Tranque P, Calvo S. Selenoprotein S expression in reactive astrocytes following brain injury. Glia. 2011;59(6):959–72.CrossRefPubMed
18.
Christensen LC, Jensen NW, Vala A, Kamarauskaite J, Johansson L, Winther JR, Hofmann K, Teilum K, Ellgaard L. The human selenoprotein VCP-interacting membrane protein (VIMP) is non-globular and harbors a reductase function in an intrinsically disordered region. J Biol Chem. 2012;287(31):26388–99.CrossRefPubMedPubMedCentral
19.
Gao Y, Feng HC, Walder K, Bolton K, Sunderland T, Bishara N, Quick M, Kantham L, Collier GR. Regulation of the selenoprotein SelS by glucose deprivation and endoplasmic reticulum stress—SelS is a novel glucose-regulated protein. FEBS Lett. 2004;563(1–3):185–90.CrossRefPubMed
20.
Shchedrina VA, Zhang Y, Labunskyy VM, Hatfield DL, Gladyshev VN. Structure–function relations, physiological roles, and evolution of mammalian ER-resident selenoproteins. Antioxid Redox Signal. 2010;12(7):839–49.CrossRefPubMedPubMedCentral
21.
Kim KH, Gao Y, Walder K, Collier GR, Skelton J, Kissebah AH. SEPS1 protects RAW264.7 cells from pharmacological ER stress agent-induced apoptosis. Biochem Biophys Res Commun. 2007;354(1):127–32.CrossRefPubMedPubMedCentral
22.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.CrossRefPubMed
23.
Rani V, Deep G, Singh RK, Palle K, Yadav UC. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93.CrossRefPubMed
24.
Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV. Role of endoplasmic reticulum stress in atherosclerosis and diabetic macrovascular complications. Biomed Res Int. 2014;2014:610140.PubMedPubMedCentral
25.
26.
Bubenik JL, Miniard AC, Driscoll DM. Alternative transcripts and 3′UTR elements govern the incorporation of selenocysteine into selenoprotein S. PLoS ONE. 2013;8(4):e62102.CrossRefPubMedPubMedCentral
27.
Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9(7):775–806.CrossRefPubMed
28.
Driscoll DM, Copeland PR. Mechanism and regulation of selenoprotein synthesis. Annu Rev Nutr. 2003;23:17–40.CrossRefPubMed
29.
Hatfield DL, Carlson BA, Xu XM, Mix H, Gladyshev VN. Selenocysteine incorporation machinery and the role of selenoproteins in development and health. Prog Nucleic Acid Res Mol Biol. 2006;81:97–142.CrossRefPubMed
30.
31.
Lin HC, Ho SC, Chen YY, Khoo KH, Hsu PH, Yen HC. SELENOPROTEINS. CRL2 aids elimination of truncated selenoproteins produced by failed UGA/Sec decoding. Science. 2015;349(6243):91–5.CrossRefPubMedPubMedCentral
32.
Gao Y, Pagnon J, Feng HC, Konstantopolous N, Jowett JB, Walder K, Collier GR. Secretion of the glucose-regulated selenoprotein SEPS1 from hepatoma cells. Biochem Biophys Res Commun. 2007;356(3):636–41.CrossRefPubMed
33.
Yu SS, Men LL, Wu JL, Huang LW, Xing Q, Yao JJ, Wang YB, Song GR, Guo HS, Sun GH, et al. The source of circulating selenoprotein S and its association with type 2 diabetes mellitus and atherosclerosis: a preliminary study. Cardiovasc Diabetol. 2016;15:70.CrossRefPubMedPubMedCentral
34.
Gao Y, Walder K, Sunderland T, Kantham L, Feng HC, Quick M, Bishara N, de Silva A, Augert G, Tenne-Brown J, et al. Elevation in Tanis expression alters glucose metabolism and insulin sensitivity in H4IIE cells. Diabetes. 2003;52(4):929–34.CrossRefPubMed
35.
Zhang N, Jing W, Cheng J, Cui W, Mu Y, Li K, Lei X. Molecular characterization and NF-kappaB-regulated transcription of selenoprotein S from the Bama mini-pig. Mol Biol Rep. 2011;38(7):4281–6.CrossRefPubMed
36.
Zhang Y, Zhou Y, Schweizer U, Savaskan NE, Hua D, Kipnis J, Hatfield DL, Gladyshev VN. Comparative analysis of selenocysteine machinery and selenoproteome gene expression in mouse brain identifies neurons as key functional sites of selenium in mammals. J Biol Chem. 2008;283(4):2427–38.CrossRefPubMed
37.
Windmill K, Tenne-Brown J, Bayles R, Trevaskis J, Gao Y, Walder K, Collier GR. Localization and expression of selenoprotein S in the testis of Psammomys obesus. J Mol Histol. 2007;38(1):97–101.CrossRefPubMed
38.
Speckmann B, Gerloff K, Simms L, Oancea I, Shi W, McGuckin MA, Radford-Smith G, Khanna KK. Selenoprotein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cells. Free Radic Biol Med. 2014;67:265–77.CrossRefPubMed
39.
Hao S, Hu J, Song S, Huang D, Xu H, Qian G, Gan F, Huang K. Selenium alleviates aflatoxin B1-induced immune toxicity through improving glutathione peroxidase 1 and selenoprotein S expression in primary porcine splenocytes. J Agric Food Chem. 2016;64(6):1385–93.CrossRefPubMed
40.
Du JL, An LJ, Sun CK, Men LL, Zhang XJ, Li CC. Overexpressing SelS may protect human umbilical vein endothelial cells from injuring by H2O2. Prog Biochem Biophys. 2007;34(4):425–30.
41.
Zhao Y, Li H, Men LL, Huang RC, Zhou HC, Xing Q, Yao JJ, Shi CH, Du JL. Effects of selenoprotein S on oxidative injury in human endothelial cells. J Transl Med. 2013;11:287.CrossRefPubMedPubMedCentral
42.
Ye Y, Fu F, Li X, Yang J, Liu H. Selenoprotein S is highly expressed in the blood vessels and prevents vascular smooth muscle cells from apoptosis. J Cell Biochem. 2016;117(1):106–17.CrossRefPubMed
43.
Zeng J, Du S, Zhou J, Huang K. Role of SelS in lipopolysaccharide-induced inflammatory response in hepatoma HepG2 cells. Arch Biochem Biophys. 2008;478(1):1–6.CrossRefPubMed
44.
Liu LX, Zhou XY, Li CS, Liu LQ, Huang SY, Zhou SN. Selenoprotein S expression in the rat brain following focal cerebral ischemia. Neurol Sci Offi J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2013;34(9):1671–8.
45.
Stoedter M, Renko K, Hog A, Schomburg L. Selenium controls the sex-specific immune response and selenoprotein expression during the acute-phase response in mice. Biochem J. 2010;429(1):43–51.CrossRefPubMed
46.
Tsuji PA, Carlson BA, Anderson CB, Seifried HE, Hatfield DL, Howard MT. Dietary selenium levels affect selenoprotein expression and support the interferon-gamma and IL-6 immune response pathways in mice. Nutrients. 2015;7(8):6529–49.CrossRefPubMedPubMedCentral
47.
Su MS, He L, Yao YM, Yu Y, Wu Y, Dong JH. Altered hepatic expression of selenoprotein S1 in septic mouse induced by LPS attack. Zhonghua yi xue za zhi. 2010;90(26):1841–4.PubMed
48.
Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, Abel Azim DM, Cai G, Mahaney MC, Comuzzie AG, et al. Genetic variation in selenoprotein S influences inflammatory response. Nat Genet. 2005;37(11):1234–41.CrossRefPubMed
49.
Seiderer J, Dambacher J, Kuhnlein B, Pfennig S, Konrad A, Torok HP, Haller D, Goke B, Ochsenkuhn T, Lohse P, et al. The role of the selenoprotein S (SELS) gene −105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation. Tissue Antigens. 2007;70(3):238–46.CrossRefPubMed
50.
Bos SD, Kloppenburg M, Suchiman E, van Beelen E, Slagboom PE, Meulenbelt I. The role of plasma cytokine levels, CRP and selenoprotein S gene variation in OA. Osteoarthr Cartil OARS, Osteoarthr Res Soc. 2009;17(5):621–6.CrossRef
51.
52.
Touat-Hamici Z, Legrain Y, Bulteau AL, Chavatte L. Selective up-regulation of human selenoproteins in response to oxidative stress. J Biol Chem. 2014;289(21):14750–61.CrossRefPubMedPubMedCentral
53.
Gan F, Hu Z, Huang Y, Xue H, Huang D, Qian G, Hu J, Chen X, Wang T, Huang K. Overexpression of pig selenoprotein S blocks OTA-induced promotion of PCV2 replication by inhibiting oxidative stress and p38 phosphorylation in PK15 cells. Oncotarget. 2016;7:20469.CrossRefPubMedPubMedCentral
54.
Noda C, Kimura H, Arasaki K, Matsushita M, Yamamoto A, Wakana Y, Inoue H, Tagaya M. Valosin-containing protein-interacting membrane protein (VIMP) links the endoplasmic reticulum with microtubules in concert with cytoskeleton-linking membrane protein (CLIMP)-63. J Biol Chem. 2014;289(35):24304–13.CrossRefPubMedPubMedCentral
55.
Schulze A, Standera S, Buerger E, Kikkert M, van Voorden S, Wiertz E, Koning F, Kloetzel PM, Seeger M. The ubiquitin–domain protein HERP forms a complex with components of the endoplasmic reticulum associated degradation pathway. J Mol Biol. 2005;354(5):1021–7.CrossRefPubMed
56.
Ye Y, Shibata Y, Kikkert M, van Voorden S, Wiertz E, Rapoport TA. Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proc Natl Acad Sci. 2005;102(40):14132–8.CrossRefPubMedPubMedCentral
57.
Turanov AA, Shchedrina VA, Everley RA, Lobanov AV, Yim SH, Marino SM, Gygi SP, Hatfield DL, Gladyshev VN. Selenoprotein S is involved in maintenance and transport of multiprotein complexes. Biochem J. 2014;462(3):555–65.CrossRefPubMed
58.
Lee JH, Kwon JH, Jeon YH, Ko KY, Lee SR, Kim IY. Pro178 and Pro183 of selenoprotein S are essential residues for interaction with p97(VCP) during endoplasmic reticulum-associated degradation. J Biol Chem. 2014;289(20):13758–68.CrossRefPubMedPubMedCentral
59.
Lee JH, Park KJ, Jang JK, Jeon YH, Ko KY, Kwon JH, Lee SR, Kim IY. Selenoprotein S-dependent selenoprotein K binding to p97(VCP) protein is essential for endoplasmic reticulum-associated degradation. J Biol Chem. 2015;290(50):29941–52.CrossRefPubMedPubMedCentral
60.
Fradejas N, Pastor MD, Mora-Lee S, Tranque P, Calvo S. SEPS1 gene is activated during astrocyte ischemia and shows prominent antiapoptotic effects. J Mol Neurosci MN. 2008;35(3):259–65.CrossRefPubMed
61.
Du S, Liu H, Huang K. Influence of SelS gene silence on beta-mercaptoethanol-mediated endoplasmic reticulum stress and cell apoptosis in HepG2 cells. Biochem Biophys Acta. 2010;1800(5):511–7.CrossRefPubMed
62.
Qin HS, Yu PP, Sun Y, Wang DF, Deng XF, Bao YL, Song J, Sun LG, Song ZB, Li YX. Paclitaxel inhibits selenoprotein S expression and attenuates endoplasmic reticulum stress. Mol Med Rep. 2016;13(6):5118–24.PubMedPubMedCentral
63.
Kelly E, Greene CM, Carroll TP, McElvaney NG, O’Neill SJ. Selenoprotein S/SEPS1 modifies endoplasmic reticulum stress in Z variant alpha1-antitrypsin deficiency. J Biol Chem. 2009;284(25):16891–7.CrossRefPubMedPubMedCentral
64.
65.
Martinez A, Santiago JL, Varade J, Marquez A, Lamas JR, Mendoza JL, de la Calle H, Diaz-Rubio M, de la Concha EG, Fernandez-Gutierrez B, et al. Polymorphisms in the selenoprotein S gene: lack of association with autoimmune inflammatory diseases. BMC Genom. 2008;9:329.CrossRef
66.
Olsson M, Olsson B, Jacobson P, Thelle DS, Bjorkegren J, Walley A, Froguel P, Carlsson LM, Sjoholm K. Expression of the selenoprotein S (SELS) gene in subcutaneous adipose tissue and SELS genotype are associated with metabolic risk factors. Metab Clin Exp. 2011;60(1):114–20.CrossRefPubMedPubMedCentral
67.
Karlsson HK, Tsuchida H, Lake S, Koistinen HA, Krook A. Relationship between serum amyloid A level and Tanis/SelS mRNA expression in skeletal muscle and adipose tissue from healthy and type 2 diabetic subjects. Diabetes. 2004;53(6):1424–8.CrossRefPubMed
68.
Du JL, Sun CK, Lu B, Men LL, Yao JJ, An LJ, Song GR. Association of SelS mRNA expression in omental adipose tissue with Homa-IR and serum amyloid A in patients with type 2 diabetes mellitus. Chin Med J. 2008;121(13):1165–8.PubMed
69.
Du JL, Liu JF, Men LL, Yao JJ, Sun LP, Sun GH, Song GR, Yang Y, Bai R, Xing Q, et al. Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus. Chin Med J. 2009;122(21):2560–6.PubMed
70.
Marzi C, Huth C, Herder C, Baumert J, Thorand B, Rathmann W, Meisinger C, Wichmann HE, Roden M, Peters A, et al. Acute-phase serum amyloid A protein and its implication in the development of type 2 diabetes in the KORA S4/F4 study. Diabetes Care. 2013;36(5):1321–6.CrossRefPubMedPubMedCentral
71.
Hyrenbach S, Pezzini A, del Zotto E, Giossi A, Lichy C, Kloss M, Werner I, Padovani A, Brandt T, Grond-Ginsbach C. No association of the −105 promoter polymorphism of the selenoprotein S encoding gene SEPS1 with cerebrovascular disease. Eur J Neurol. 2007;14(10):1173–5.CrossRefPubMed
72.
Alanne M, Kristiansson K, Auro K, Silander K, Kuulasmaa K, Peltonen L, Salomaa V, Perola M. Variation in the selenoprotein S gene locus is associated with coronary heart disease and ischemic stroke in two independent finnish cohorts. Hum Genet. 2007;122(3–4):355–65.CrossRefPubMed
73.
Li XX, Guan HJ, Liu JP, Guo YP, Yang Y, Niu YY, Yao LY, Yang YD, Yue HY, Meng LL, et al. Association of selenoprotein S gene polymorphism with ischemic stroke in a Chinese case–control study. Blood Coagul Fibrinol Int J Haemost Thromb. 2015;26(2):131–5.CrossRef
74.
Silander K, Alanne M, Kristiansson K, Saarela O, Ripatti S, Auro K, Karvanen J, Kulathinal S, Niemela M, Ellonen P, et al. Gender differences in genetic risk profiles for cardiovascular disease. PLoS ONE. 2008;3(10):e3615.CrossRefPubMedPubMedCentral
75.
Cox AJ, Lehtinen AB, Xu J, Langefeld CD, Freedman BI, Carr JJ, Bowden DW. Polymorphisms in the selenoprotein S gene and subclinical cardiovascular disease in the Diabetes Heart Study. Acta Diabetol. 2013;50(3):391–9.CrossRefPubMed
76.
Ruggiero D, Paolillo S, Ratta GD, Mariniello A, Formisano T, Pellegrino AM, Filardi PP. Endothelial function as a marker of pre-clinical atherosclerosis: assessment techniques and clinical implications. Monaldi Arch Chest Dis = Archivio Monaldi per le malattie del torace/Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Universita di Napoli, Secondo ateneo. 2013;80(3):106–10.
77.
Tousoulis D, Simopoulou C, Papageorgiou N, Oikonomou E, Hatzis G, Siasos G, Tsiamis E, Stefanadis C. Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches. Pharmacol Ther. 2014;144(3):253–67.CrossRefPubMed
78.
Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RT, Heyll K, Noels H, Hristov M, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4):368–76.CrossRefPubMedPubMedCentral
79.
Rotllan N, Wanschel AC, Fernandez-Hernando A, Salerno AG, Offermanns S, Sessa WC, Fernandez-Hernando C. Genetic evidence supports a major role for Akt1 in VSMCs during atherogenesis. Circ Res. 2015;116(11):1744–52.CrossRefPubMedPubMedCentral
80.
Shibata T, Arisawa T, Tahara T, Ohkubo M, Yoshioka D, Maruyama N, Fujita H, Kamiya Y, Nakamura M, Nagasaka M, et al. Selenoprotein S (SEPS1) gene −105G>A promoter polymorphism influences the susceptibility to gastric cancer in the Japanese population. BMC Gastroenterol. 2009;9:2.CrossRefPubMedPubMedCentral
81.
Mao H, Cui R, Wang X. Association analysis of selenoprotein S polymorphisms in Chinese Han with susceptibility to gastric cancer. Int J Clin Exp Med. 2015;8(7):10993–9.PubMedPubMedCentral
82.
Meplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, Hlavata I, Vrana D, Vodicka P, Hesketh JE. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis. 2010;31(6):1074–9.CrossRefPubMed
83.
Sutherland A, Kim DH, Relton C, Ahn YO, Hesketh J. Polymorphisms in the selenoprotein S and 15-kDa selenoprotein genes are associated with altered susceptibility to colorectal cancer. Genes Nutr. 2010;5(3):215–23.CrossRefPubMedPubMedCentral
84.
Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2011;71(2):123–9.CrossRefPubMed
85.
Marinou I, Walters K, Dickson MC, Binks MH, Bax DE, Wilson AG. Evidence of epistasis between interleukin 1 and selenoprotein-S with susceptibility to rheumatoid arthritis. Ann Rheum Dis. 2009;68(9):1494–7.CrossRefPubMed
86.
Santos LR, Duraes C, Mendes A, Prazeres H, Alvelos MI, Moreira CS, Canedo P, Esteves C, Neves C, Carvalho D, et al. A polymorphism in the promoter region of the selenoprotein S gene (SEPS1) contributes to Hashimoto’s thyroiditis susceptibility. J Clin Endocrinol Metabol. 2014;99(4):E719–23.CrossRef
87.
Li M, Liu B, Li L, Zhang C, Zhou Q. Association studies of SEPS1 gene polymorphisms with Hashimoto’s thyroiditis in Han Chinese. J Hum Genet. 2015;60(8):427–33.CrossRefPubMed
88.
Moses EK, Johnson MP, Tommerdal L, Forsmo S, Curran JE, Abraham LJ, Charlesworth JC, Brennecke SP, Blangero J, Austgulen R. Genetic association of preeclampsia to the inflammatory response gene SEPS1. Am J Obstet Gynecol. 2008;198(3):336.CrossRefPubMed
89.
Wang Y, Yang X, Zheng Y, Wu ZH, Zhang XA, Li QP, He XY, Wang CZ, Feng ZC. The SEPS1 G-105A polymorphism is associated with risk of spontaneous preterm birth in a Chinese population. PLoS ONE. 2013;8(6):e65657.CrossRefPubMedPubMedCentral
90.
Du XA, Wang HM, Dai XX, Kou Y, Wu RP, Chen Q, Cao JL, Mo XY, Xiong YM. Role of selenoprotein S (SEPS1) −105G>A polymorphisms and PI3K/Akt signaling pathway in Kashin–Beck disease. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2015;23(2):210–6.CrossRef
Metadata
Title
Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?
Authors
Shan-shan Yu
Jian-ling Du
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2017
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-017-0585-8

Other articles of this Issue 1/2017

Cardiovascular Diabetology 1/2017 Go to the issue

Original investigation

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

Original investigation

High-density lipoproteins attenuate high glucose-impaired endothelial cell signaling and functions: potential implications for improved vascular repair in diabetes

Original investigation

Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus

Original investigation

Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure

Original investigation

Changes in proteinuria and the risk of myocardial infarction in people with diabetes or pre-diabetes: a prospective cohort study

Original investigation

The effect of exercise training on clinical outcomes in patients with the metabolic syndrome: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits